Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation.

Journal Article (Journal Article)

BACKGROUND: This study examines the impact of donor liver macrovesicular steatosis on recurrence of hepatitis C virus (HCV) disease after liver transplantation. METHODS: Between 1998 and 2004, 113 patients underwent liver transplantation for HCV-related cirrhosis. Time to histologic recurrence (fibrosis score >or=2) was the primary endpoint of the study. Recurrence was graded according to the system of Ludwig and Batts. A Cox's proportional hazard regression model was used to analyse the association between donor liver steatosis and HCV recurrence. RESULTS: Recurrence-free survival for patients who received steatotic grafts was 82% and 47% at 1 and 4 years, respectively, and 81% and 52% for patients who received a non-steatotic liver. Donor macrovesicular steatosis (5-45%) was found to have no impact on HCV recurrence (P=0.47). Donor age (P=0.02) and cold ischaemia time (P=0.01) were found to increase the relative risk of HCV recurrence. The estimated risk of HCV recurrence increased by 23% for every 10-year increase in donor age. Similarly the risk of recurrence increased by 13% for every 1-h increase in cold ischaemia time. CONCLUSION: Mild-moderate donor liver macrovesicular steatosis has no impact on HCV recurrence after liver transplantation for HCV-related cirrhosis. Cold ischaemia time and donor age increased the likelihood of HCV recurrence.

Full Text

Duke Authors

Cited Authors

  • Botha, JF; Thompson, E; Gilroy, R; Grant, WJ; Mukherjee, S; Lyden, ER; Fox, IJ; Sudan, DL; Shaw, BW; Langnas, AN

Published Date

  • August 2007

Published In

Volume / Issue

  • 27 / 6

Start / End Page

  • 758 - 763

PubMed ID

  • 17617118

International Standard Serial Number (ISSN)

  • 1478-3223

Digital Object Identifier (DOI)

  • 10.1111/j.1478-3231.2007.01490.x


  • eng

Conference Location

  • United States